New to Meducation?
Sign up
Already signed up? Log In
view moderators

MultipleSclerosis

Category

Edfbb3574815bd21e45dcb09148fc13a8ddaa59f2905147473686679
7
1987

Diagnosing and Treating Neuromyelitis Optica

Excellent Podcast on diagnosing and treating neuromyelitis optica by BMJ talk medicine.  
SoundCloud
about 5 years ago
Preview
1
114

Multiple Sclerosis (MS) | almostadoctor

MS is an inflammatory condition that affects the oligodendrocites of the CNS. Peripheral nerves are not affected.  
almostadoctor.com - free medical student revision notes
about 5 years ago
Www.bmj
1
16

Simvastatin shows promise in treating progressive multiple sclerosis, study finds

High doses of the cholesterol lowering drug simvastatin over two years led to reduced brain shrinkage in people with secondary progressive multiple sclerosis when compared with placebo, a study has found, and the researchers have called for trials to investigate the drug’s effect on disability.  
bmj.com
about 5 years ago
Www.bmj
1
17

Removal of access to alemtuzumab for patients with aggressive multiple sclerosis

Although some treatments are now available for multiple sclerosis, better treatments are needed for people with aggressive disease. The need to find agents that can prevent or slow disease progression is particularly challenging and requires a concerted global effort that combines academic and pharmaceutical expertise. Although such partnerships are rare, the story of alemtuzumab has shown, inspirationally, that academic and pharmaceutical prowess can be combined to deliver an agent with real promise. Alemtuzumab, which has been used successfully off label to treat active relapsing-remitting multiple sclerosis, is a humanised monoclonal antibody that targets the CD52 antigen on leucocytes. Not surprisingly, there was therefore an outcry when Genzyme, now a Sanofi company, surrendered the licence for all currently licensed preparations of alemtuzumab, with effect from 8 August 2012, meaning that it will no longer be available as a licensed product in the United Kingdom once existing supplies run out.1 2  
bmj.com
about 5 years ago
Www.bmj
1
20

Cancer drug shows promise for multiple sclerosis

Two manufacturer sponsored phase III trials suggest that alemtuzumab, an anti-CD52 monoclonal antibody that is licensed to treat leukaemia, may help control multiple sclerosis. Both trials lasted two years and compared alemtuzumab with interferon beta-1a, which is considered first line treatment. One trial looked at 563 patients who had not yet undergone treatment for multiple sclerosis, whereas the other trial looked at …  
bmj.com
about 5 years ago
Www.bmj
1
21

Another promising oral agent for multiple sclerosis

Dimethyl fumerate has a chequered history⇑. It was banned as an industrial fungicide in the late 1990s, after furniture impregnated with fumarate caused outbreaks of serious allergic eczema. However, it remains an effective treatment for psoriasis when …  
bmj.com
about 5 years ago
Www.bmj
2
116

Vitamin D: some perspective please

Vitamin D deficiency has been associated with an ever expanding list of diseases, and with this has come almost tonic-like claims for vitamin D supplementation. In observational studies, low vitamin D status has been associated with increased risk of multiple sclerosis, type 1 and type 2 diabetes, cardiovascular disease, colon cancer, breast cancer, autoimmunity, and allergy.1 The UK government has advised that all pregnant women, and children under 5 years, should take 400 IU vitamin D daily; a recent news story, however, reported a survey conducted by a charity which suggested that only 26% of pregnant women and 46% of healthcare professionals are aware of these guidelines.2 The most recent musculoskeletal trend seems to be the attribution of childhood problems such as Blount’s disease and slipped femoral epiphyses to vitamin D deficiency and the incorrect conflation of rickets with low serum calcidiol (25-hydroxyvitamin D3) concentrations.3 So are health professionals causing ill health through their lack of awareness and advocacy of vitamin D supplementation?  
bmj.com
about 5 years ago
Preview
1
33

Stopping Multiple Sclerosis - The Naked Scientists

Naked Scientists - 12th Nov 2013 - Stopping Multiple Sclerosis  
thenakedscientists.com
about 5 years ago
Www.bmj
1
20

What is a crossover trial?

Researchers evaluated the effectiveness of the cannabinoid dronabinol on central neuropathic pain in patients with multiple sclerosis.[1] The effectiveness of cannabinoids in relieving pain caused by central lesions in multiple sclerosis had not been investigated previously. A randomised double blind placebo controlled crossover trial study design was used. The intervention was orally administered dronabinol at a maximum dose of 10 mg daily or corresponding placebo. Each treatment period was for three weeks, separated by a three week washout period. All analgesic drugs, except for paracetamol, were discontinued at least one week before the start of the trial.  
bmj.com
about 5 years ago
Preview
1
27

Multiple sclerosis discovery may explain gender gap - BBC News

Research into mice and people with multiple sclerosis (MS) says a key difference in male and female brains may explain why more women get the disease than men.  
BBC News
about 5 years ago
Www.bmj
1
14

What is a crossover trial?

Researchers evaluated the effectiveness of the cannabinoid dronabinol on central neuropathic pain in patients with multiple sclerosis.[1] The effectiveness of cannabinoids in relieving pain caused by central lesions in multiple sclerosis had not been investigated previously. A randomised double blind placebo controlled crossover trial study design was used. The intervention was orally administered dronabinol at a maximum dose of 10 mg daily or corresponding placebo. Each treatment period was for three weeks, separated by a three week washout period. All analgesic drugs, except for paracetamol, were discontinued at least one week before the start of the trial.  
bmj.com
about 5 years ago
Www.bmj
1
18

What is a crossover trial?

Researchers evaluated the effectiveness of the cannabinoid dronabinol on central neuropathic pain in patients with multiple sclerosis.[1] The effectiveness of cannabinoids in relieving pain caused by central lesions in multiple sclerosis had not been investigated previously. A randomised double blind placebo controlled crossover trial study design was used. The intervention was orally administered dronabinol at a maximum dose of 10 mg daily or corresponding placebo. Each treatment period was for three weeks, separated by a three week washout period. All analgesic drugs, except for paracetamol, were discontinued at least one week before the start of the trial.  
bmj.com
about 5 years ago
Www.bmj
1
16

What is a crossover trial?

Researchers evaluated the effectiveness of the cannabinoid dronabinol on central neuropathic pain in patients with multiple sclerosis.[1] The effectiveness of cannabinoids in relieving pain caused by central lesions in multiple sclerosis had not been investigated previously. A randomised double blind placebo controlled crossover trial study design was used. The intervention was orally administered dronabinol at a maximum dose of 10 mg daily or corresponding placebo. Each treatment period was for three weeks, separated by a three week washout period. All analgesic drugs, except for paracetamol, were discontinued at least one week before the start of the trial.  
bmj.com
about 5 years ago
Preview
1
32

HIV and multiple sclerosis: beginning to unravel a mystery

Stream HIV and multiple sclerosis: beginning to unravel a mystery by BMJ talk medicine from desktop or your mobile device  
SoundCloud
over 4 years ago
Preview
1
25

Brain atrophy and disability progression in multiple sclerosis patients

Stream Brain atrophy and disability progression in multiple sclerosis patients by BMJ talk medicine from desktop or your mobile device  
SoundCloud
over 4 years ago
Artworks 000093832160 yhp6i1 t500x500
1
18

Brain atrophy and disability progression in multiple sclerosis patients

Stream Brain atrophy and disability progression in multiple sclerosis patients by BMJ talk medicine from desktop or your mobile device  
SoundCloud
over 4 years ago
Artworks 000099901681 zvamh2 t500x500
1
9

Imaging outcomes for trials of remyelination in multiple sclerosis

Trials of potential neuroreparative agents are becoming more important in the spectrum of multiple sclerosis research. Appropriate imaging outcomes are required that are feasible from a time and pract  
SoundCloud
over 4 years ago
Preview
2
30

Diagnosing and treating neuromyelitis optica

Stream Diagnosing and treating neuromyelitis optica by BMJ talk medicine from desktop or your mobile device  
SoundCloud
over 4 years ago
Www.bmj
1
22

Bias in observational study designs: case-control studies

Researchers investigated the association between sun exposure and risk of multiple sclerosis. A population based case-control study was performed. The participants were recruited from residents of Tasmania, Australia, who were aged under 60 years and had at least one grandparent born in Tasmania. Cases were people with multiple sclerosis who volunteered after information evenings at local multiple sclerosis societies, or after having been invited by a healthcare professional. In total, 136 people with a diagnosis of multiple sclerosis, as defined by clinical and magnetic resonance imaging criteria, were included as cases. For each case, two controls matched for sex and year of birth were randomly selected from the community. In total, 359 eligible controls were approached and the response rate was 76%.1  
bmj.com
about 4 years ago
Www.bmj
1
21

Measuring the burden of treatment

Increasing pressure is put on patients to self manage,1 despite a dearth of robust tools to help them do this, thereby setting up many patients for failure. Many newer treatments involve self injections or infusions, and these can be extremely challenging—for example, up to 15% of patients with multiple sclerosis were unable to inject …  
bmj.com
about 4 years ago